ECS Role in Depression & Pain
Gooey Rabinski
Founder at Higher Learning LV and technical writer and instructional developer
"I love your articles. Informative, rich, clean. Amazing work." — Miriam Sanger, cannabis journalist, Ra'ananna, Central, Israel, August 2020
"If you aren’t following Curt Robbins, you are missing out on one of the smartest people in cannabis." — Cannabis & Tech Today Magazine, 2020
"Curt Robbins from California is an encyclopedia of cannabis knowledge." — Ian Jessop, Cannabis Health Radio, 2017
It is estimated that major depressive disorder affects nearly 20 million Americans (including two million children between the ages of three and 17). In addition, 50 million Americans (nearly 20 percent of the population) suffer from chronic pain. A wide collection of research studies has revealed the intimate role played by the ECS with respect to these common physical and psychological diseases.
A 2018 study entitled “Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression” investigated the role of anandamide and 2-AG in regulating mood, including depression and anxiety. “A number of emotions and behaviors, such as fear, anxiety, [and] depression...are critically modulated by the ECS,” reported the study’s authors.
The researchers found a connection between the levels of endocannabinoids such as 2-AG and depression. “In patients with major depression, reduced circulating levels of both 2-AG and AEA [anandamide] have been [observed].” The study concluded, “Emotional homeostasis is crucially modulated by the activity of the ECS.”
- To continue reading this article, visit Higher Learning LV.
About The Author
Curt Robbins is a technical writer, instructional designer, and lecturer who has been developing science-based educational and training content for Fortune 200 enterprises for more than 30 years. His clients have included Federal Express, Microsoft, Sun Microsystems, Northrop Grumman, National City Bank, Strainprint Technologies Ltd., the J.M. Smucker Company, and USAA.
Robbins has developed more than 600 educational articles regarding hemp and its various health components, including terpenes, cannabinoids, and the human endocannabinoid system for clients in the U.S., Canada, and Israel. His latest white paper, CBG: The Mother of Cannabinoids, is an evidence-based 50-page deep dive into the biochemistry of the hemp-derived phytocannabinoid cannabigerol that features 60 peer-reviewed research study citations.
Robbins currently serves as Director of Curriculum Development for Higher Learning LV? based in Las Vegas, Nevada. Robbins can be found on Twitter at @RobbinsGroupLLC and via email at [email protected]. To learn more, search for his social media hashtag campaigns on your favorite social media network:
- #LearnAndTeachOthers?
- #TeachYourselfTerpenes?
